Ken Griffin Corvus Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,000 shares of CRVS stock, worth $70,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,000

Previous 14,900 46.31%

Holding current value

$70,320

Previous $26,000 46.15%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $72,093 - $121,392	53,010 New	53,010 $96,000
Q4 2023 Feb 14, 2024	BUY	$1.08 - $1.92 $8,068 - $14,344	7,471 Added 4082.51%	7,654 $13,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.97 $258 - $543	183 New	183 $0
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.04 $751 - $1,055	1,015 New	1,015 $0
Q1 2022 May 16, 2022	BUY	$1.46 - $2.48 $491,238 - $834,433	336,465 Added 494.22%	404,545 $663,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $90,796 - $206,038	38,802 Added 132.53%	68,080 $164,000
Q2 2021 Aug 16, 2021	SELL	$2.46 - $3.14 $86,082 - $109,878	-34,993 Reduced 54.45%	29,278 $78,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.77 $183,815 - $306,572	64,271 New	64,271 $198,000
Q3 2020 Nov 16, 2020	SELL	$2.6 - $5.37 $40,349 - $83,337	-15,519 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.01 - $4.05 $59,783 - $120,459	-29,743 Reduced 65.71%	15,519 $42,000
Q1 2020 May 15, 2020	BUY	$1.74 - $5.98 $49,342 - $169,580	28,358 Added 167.76%	45,262 $95,000
Q4 2018 Feb 14, 2019	SELL	$3.29 - $8.94 $14,344 - $38,978	-4,360 Reduced 20.5%	16,904 $62,000
Q3 2018 Nov 13, 2018	BUY	$8.58 - $11.4 $182,445 - $242,409	21,264 New	21,264 $0

Others Institutions Holding CRVS

# of Institutions

Shares Held

27.8M

Call Options Held

22.9K

Put Options Held

29.8K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $409M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account